<?xml version='1.0' encoding='utf-8'?>
<document id="32275773"><sentence text="P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients."><entity charOffset="38-48" id="DDI-PubMed.32275773.s1.e0" text="Paclitaxel" /></sentence><sentence text="Paclitaxel-induced peripheral neuropathy (PIPN) is a common and dose-limiting adverse event"><entity charOffset="0-10" id="DDI-PubMed.32275773.s2.e0" text="Paclitaxel" /></sentence><sentence text=" The role of P-glycoprotein (P-gp) in the neuronal efflux of paclitaxel was assessed using a translational approach"><entity charOffset="61-71" id="DDI-PubMed.32275773.s3.e0" text="paclitaxel" /></sentence><sentence text=" SH-SY5Y cells were differentiated to neurons and paclitaxel toxicity in the absence and presence of a P-gp inhibitor was determined"><entity charOffset="50-60" id="DDI-PubMed.32275773.s4.e0" text="paclitaxel" /></sentence><sentence text=" Paclitaxel caused marked dose-dependent toxicity in SH-SY5Y-derived neurons"><entity charOffset="1-11" id="DDI-PubMed.32275773.s5.e0" text="Paclitaxel" /></sentence><sentence text=" Paclitaxel neurotoxicity was exacerbated with concomitant P-gp inhibition by valspodar and verapamil, consistent with increased intracellular accumulation of paclitaxel"><entity charOffset="1-11" id="DDI-PubMed.32275773.s6.e0" text="Paclitaxel" /><entity charOffset="159-169" id="DDI-PubMed.32275773.s6.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.32275773.s6.e0" e2="DDI-PubMed.32275773.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32275773.s6.e0" e2="DDI-PubMed.32275773.s6.e1" /></sentence><sentence text=" Cancer patients treated with paclitaxel and P-gp inhibitors had a 2"><entity charOffset="30-40" id="DDI-PubMed.32275773.s7.e0" text="paclitaxel" /></sentence><sentence text="4-fold (95% confidence interval (CI): 1" /><sentence text="3-4" /><sentence text="3) increased risk of peripheral neuropathy-induced dose modification, a 4" /><sentence text="7-fold (95% CI: 1" /><sentence text="9-11" /><sentence text="9) increased risk for patients treated with strong P-gp inhibitors and a 7" /><sentence text="0-fold (95% CI: 2" /><sentence text="3-21" /><sentence text="5) increased risk in patients treated with atorvastatin"><entity charOffset="43-55" id="DDI-PubMed.32275773.s16.e0" text="atorvastatin" /></sentence><sentence text=" Atorvastatin also increased neurotoxicity by paclitaxel in SH-SY5Y-derived neurons"><entity charOffset="1-13" id="DDI-PubMed.32275773.s17.e0" text="Atorvastatin" /><entity charOffset="46-56" id="DDI-PubMed.32275773.s17.e1" text="paclitaxel" /><pair ddi="false" e1="DDI-PubMed.32275773.s17.e0" e2="DDI-PubMed.32275773.s17.e0" /><pair ddi="false" e1="DDI-PubMed.32275773.s17.e0" e2="DDI-PubMed.32275773.s17.e1" /></sentence><sentence text=" Clinicians should be aware that co-medication with P-gp inhibitors may lead to increased risk of PIPN" /><sentence text="" /></document>